TWI668217B - 二氫嘧啶類化合物及其在藥物中的應用 - Google Patents

二氫嘧啶類化合物及其在藥物中的應用 Download PDF

Info

Publication number
TWI668217B
TWI668217B TW102130355A TW102130355A TWI668217B TW I668217 B TWI668217 B TW I668217B TW 102130355 A TW102130355 A TW 102130355A TW 102130355 A TW102130355 A TW 102130355A TW I668217 B TWI668217 B TW I668217B
Authority
TW
Taiwan
Prior art keywords
methyl
esi
mmol
independently
carboxylic acid
Prior art date
Application number
TW102130355A
Other languages
English (en)
Chinese (zh)
Other versions
TW201408662A (zh
Inventor
張英俊
Yingjun Zhang
任青雲
Qingyun REN
劉辛昌
Xinchang LIU
辛格佛瑞德 戈爾德曼
Siegfried Goldmann
Original Assignee
廣東東陽光藥業有限公司
Sunshine Lake Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 廣東東陽光藥業有限公司, Sunshine Lake Pharma Co., Ltd. filed Critical 廣東東陽光藥業有限公司
Publication of TW201408662A publication Critical patent/TW201408662A/zh
Application granted granted Critical
Publication of TWI668217B publication Critical patent/TWI668217B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102130355A 2012-08-24 2013-08-23 二氫嘧啶類化合物及其在藥物中的應用 TWI668217B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201210303033.4 2012-08-24
CN201210303033 2012-08-24
CN201310116949 2013-04-03
CN201310116949.3 2013-04-03

Publications (2)

Publication Number Publication Date
TW201408662A TW201408662A (zh) 2014-03-01
TWI668217B true TWI668217B (zh) 2019-08-11

Family

ID=50149385

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102130355A TWI668217B (zh) 2012-08-24 2013-08-23 二氫嘧啶類化合物及其在藥物中的應用

Country Status (20)

Country Link
US (1) US9340538B2 (OSRAM)
EP (1) EP2888241B1 (OSRAM)
JP (1) JP6263533B2 (OSRAM)
KR (1) KR102148678B1 (OSRAM)
CN (2) CN104926808B (OSRAM)
AU (1) AU2013305390C1 (OSRAM)
BR (1) BR112015002858A2 (OSRAM)
CA (1) CA2876690C (OSRAM)
DK (1) DK2888241T3 (OSRAM)
ES (1) ES2640049T3 (OSRAM)
HU (1) HUE034919T2 (OSRAM)
MX (1) MX2015002511A (OSRAM)
MY (1) MY182403A (OSRAM)
PL (1) PL2888241T3 (OSRAM)
PT (1) PT2888241T (OSRAM)
RU (1) RU2655914C9 (OSRAM)
SG (1) SG11201408791TA (OSRAM)
TW (1) TWI668217B (OSRAM)
WO (1) WO2014029193A1 (OSRAM)
ZA (1) ZA201500451B (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2892893B2 (en) * 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
RU2678990C1 (ru) * 2013-11-19 2019-02-05 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
CN104650069B (zh) * 2013-11-19 2019-04-19 广东东阳光药业有限公司 4-甲基二氢嘧啶类化合物及其在药物中的应用
AU2014356986B2 (en) * 2013-11-27 2018-01-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
WO2015144093A1 (en) * 2014-03-28 2015-10-01 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
RU2693897C2 (ru) * 2014-05-30 2019-07-05 Килу Фармасьютикал Ко., Лтд. Производное на основе дигидропиримидо-кольца в качестве ингибитора hbv
WO2016012470A1 (en) * 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016124126A1 (en) * 2015-02-07 2016-08-11 Sunshine Lake Pharma Co., Ltd. Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
SI3270915T1 (sl) 2015-03-16 2020-07-31 F. Hoffmann-La Roche Ag Kombinirano zdravljenje z agonistom TLR7 in zaviralcem sestavljanja kapside HBV
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
HK1255463A1 (zh) * 2015-11-03 2019-08-16 F. Hoffmann-La Roche Ag Hbv衣壳组装抑制剂和干扰素的组合疗法
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AR107633A1 (es) 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
WO2017198201A1 (en) * 2016-05-19 2017-11-23 Sunshine Lake Pharma Co., Ltd. Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine
EP3468561A4 (en) * 2016-06-10 2019-12-04 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
CN107674072B (zh) * 2016-08-01 2020-11-24 广东东阳光药业有限公司 二氢嘧啶衍生物及其酸加成物的制备方法
CN109689059A (zh) * 2016-08-24 2019-04-26 豪夫迈·罗氏有限公司 Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
CN107793409B (zh) * 2016-09-05 2022-09-27 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
WO2018045911A1 (zh) * 2016-09-09 2018-03-15 浙江海正药业股份有限公司 二氢嘧啶类化合物及其制备方法和用途
US11166954B2 (en) 2016-11-18 2021-11-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Dihydropyrimidine compound and preparation method and use thereof
JP7139568B2 (ja) * 2016-11-18 2022-09-21 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド ジヒドロピリミジン化合物並びにその調製方法及び使用
EP3645516A4 (en) * 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
JP2020528062A (ja) 2017-07-27 2020-09-17 江蘇恒瑞医薬股▲ふん▼有限公司 ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
TWI811236B (zh) 2017-08-28 2023-08-11 美商因那塔製藥公司 B型肝炎抗病毒試劑
JP2021505132A (ja) 2017-11-30 2021-02-18 アラーキス セラピューティクス, インコーポレイテッド 核酸結合光プローブおよびその使用
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TW201936192A (zh) 2017-12-06 2019-09-16 美商因那塔製藥公司 B 型肝炎抗病毒試劑
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2019266729A1 (en) * 2018-05-08 2021-03-11 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
JP2021529188A (ja) * 2018-06-26 2021-10-28 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ジヒドロピリミジン誘導体及びhbv感染又はhbv誘導性疾患の治療におけるその使用
CN108947996B (zh) * 2018-07-12 2022-01-18 山东大学 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP3873488B1 (en) 2018-10-31 2025-03-19 The University of Sydney Pharmaceutical compositions for use in treating an hbv or hdv infection
CN109251201B (zh) * 2018-11-03 2020-06-02 深圳市第二人民医院 一种抗hbv的含氮杂环化合物
CN109232555B (zh) * 2018-11-03 2020-06-02 深圳市第二人民医院 一种抗hbv的含氧杂环化合物
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
KR102732006B1 (ko) 2019-03-25 2024-11-20 에프. 호프만-라 로슈 아게 Hbv 코어 단백질 알로스테릭 조절제 화합물의 고체 형태
MX2021011606A (es) 2019-04-02 2021-12-10 Aligos Therapeutics Inc Compuestos dirigidos a prmt5.
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US20220249647A1 (en) * 2019-06-18 2022-08-11 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CN110204539B (zh) * 2019-07-03 2021-07-23 山东大学 一种二氢嘧啶类前药及其制备方法和应用
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
EP4003355A4 (en) * 2019-07-31 2023-07-26 Janssen Sciences Ireland Unlimited Company DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN114867717A (zh) * 2019-12-20 2022-08-05 詹森药业有限公司 杂芳基二氢嘧啶衍生物和治疗乙型肝炎感染的方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2022052923A1 (zh) * 2020-09-08 2022-03-17 和博医药有限公司 二氢嘧啶类化合物、其应用
TW202246269A (zh) 2021-01-29 2022-12-01 愛爾蘭商健生科學愛爾蘭無限公司 二氫嘧啶衍生物及其用於治療hbv感染或hbv誘發的疾病之用途
CN116888118A (zh) * 2021-02-05 2023-10-13 和博医药有限公司 苯基二氢嘧啶类化合物及其应用
WO2022257942A1 (en) 2021-06-09 2022-12-15 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CN116284080A (zh) * 2023-02-23 2023-06-23 山东大学 一种含硼酸及硼酸频哪醇酯基团的二氢嘧啶类衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068641A1 (de) * 2000-03-17 2001-09-20 Bayer Aktiengesellschaft 6-aminoalkyl-dihydroppyrimidine und ihre verwendung als arzneimittel gegen virale erkrankungen
CN101575318A (zh) * 2009-06-25 2009-11-11 中国人民解放军军事医学科学院毒物药物研究所 新型二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202654A3 (en) 1985-05-20 1987-12-16 E.R. Squibb & Sons, Inc. 5-carboxy-1,4-dihydropyrimidine derivatives
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
CA2154633A1 (en) * 1995-01-25 1996-07-26 Paul Harry Sandstrom Silica reinforced rubber composition and use in tires
SE9702564D0 (sv) 1997-07-02 1997-07-02 Astra Ab New compounds
SE9702563D0 (sv) 1997-07-02 1997-07-02 Astra Ab Compounds
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
DE19817264A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
DE19817262A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
PE20110118A1 (es) * 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CN101104617B (zh) * 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
WO2008024692A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation N-oxide aryl sulfones and sulfoxides
CN101225084A (zh) 2007-01-16 2008-07-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101328170B (zh) * 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328168B (zh) * 2007-06-18 2011-09-07 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
CN101328169B (zh) * 2007-06-18 2011-05-25 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
US9968650B2 (en) * 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
WO2013019967A1 (en) 2011-08-02 2013-02-07 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
KR102056665B1 (ko) 2012-01-06 2019-12-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2892893B2 (en) * 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068641A1 (de) * 2000-03-17 2001-09-20 Bayer Aktiengesellschaft 6-aminoalkyl-dihydroppyrimidine und ihre verwendung als arzneimittel gegen virale erkrankungen
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂
CN101575318A (zh) * 2009-06-25 2009-11-11 中国人民解放军军事医学科学院毒物药物研究所 新型二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
南昌航空工業學院學報(自然科學版) 2004年09月 第18卷 第3期 41-46 *

Also Published As

Publication number Publication date
MY182403A (en) 2021-01-25
KR20150044859A (ko) 2015-04-27
ZA201500451B (en) 2016-10-26
CA2876690A1 (en) 2014-02-27
EP2888241B1 (en) 2017-07-12
PL2888241T3 (pl) 2017-12-29
HUE034919T2 (en) 2018-03-28
WO2014029193A1 (en) 2014-02-27
AU2013305390B2 (en) 2015-09-17
PT2888241T (pt) 2017-09-14
KR102148678B1 (ko) 2020-08-27
RU2655914C9 (ru) 2018-07-24
US9340538B2 (en) 2016-05-17
EP2888241A4 (en) 2016-05-25
HK1206027A1 (en) 2015-12-31
RU2015110082A (ru) 2016-10-10
CN103626752B (zh) 2015-08-12
BR112015002858A2 (pt) 2017-08-08
AU2013305390C1 (en) 2015-12-24
SG11201408791TA (en) 2015-01-29
CN104926808B (zh) 2018-09-14
AU2013305390A1 (en) 2015-01-15
CA2876690C (en) 2020-06-09
EP2888241A1 (en) 2015-07-01
JP6263533B2 (ja) 2018-01-17
US20150152096A1 (en) 2015-06-04
ES2640049T3 (es) 2017-10-31
JP2015526448A (ja) 2015-09-10
RU2655914C2 (ru) 2018-05-30
CN104926808A (zh) 2015-09-23
CN103626752A (zh) 2014-03-12
TW201408662A (zh) 2014-03-01
DK2888241T3 (en) 2017-10-23
MX2015002511A (es) 2016-03-08

Similar Documents

Publication Publication Date Title
TWI668217B (zh) 二氫嘧啶類化合物及其在藥物中的應用
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
CN103664925B (zh) 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CN103664897B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN103664899B (zh) 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
JP2020537677A (ja) ジヒドロピリミジン化合物、及び医薬におけるその使用
TW201838966A (zh) 取代的二氫茚-4-甲醯胺及其類似物以及其使用方法
CN109111451B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN101903356A (zh) 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
CN104650070B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN104650069A (zh) 4-甲基二氢嘧啶类化合物及其在药物中的应用
CN110964023A (zh) 稠合四环类化合物及其在药物中的应用
CN107793409B (zh) 二氢嘧啶类化合物及其在药物中的应用
TW202409010A (zh) 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑
HK1206027B (en) 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis